Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment

Liver International

Volumn 37, Issue , 2017, Pages 19-25

  Mücke, Marcus M ^a   Mücke, Victoria T ^a   Lange, Christian M ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

decompensated cirrhosis; hepatitis C virus; renal impairment; special populations

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; ALPHA INTERFERON;

ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE RENAL IMPAIRMENT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; COMPLICATION; HEPACIVIRUS; KIDNEY FAILURE; LIVER CIRRHOSIS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85007574295     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13279     Document Type: Review

References (65)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
2. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135.
3. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495–1504.
4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521. 21 e1-6.
5. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553–562.
6. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823–830.
7. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19:601–607.
8. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697–703.
9. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896–1902.
10. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepat Int. 2012;6:369–378.
11. Morales JM, Bloom R, Roth D. Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol. 2012;176:77–86.
12. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313.
13. Afdhal N, Asselah T, Everson G. HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment. Final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. J Hepatol. 2016;64:221–222.
14. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
15. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790–800.
16. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46:206–212.
17. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009;50:719–728.
18. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890. J Hepat. 2013;59:434–441.
19. Saxena V, Manos MM, Yee HS, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014;39:1213–1224.
20. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 27 August, 2016.
21. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725.
22. Jacobson IM, Poordad F, Firpi-Morel R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-pugh class B cirrhosis. J Hepatol. 2015;62:S193–194. (EASL abstract O008).
23. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
24. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
25. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016;doi:10.1016/j.jhep.2016.09.001 epub ahead of print.
26. Curry MP, O'leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
27. Gane E, Shiffmann M, Etzkorn K, et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A-containing DAA regimens: results of the retreatment study. Available at: http://www.natap.org/2016/EASL/EASL_11.htm.
28. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
29. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–107 e1.
30. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
31. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–1505.
32. Welzel TM, Herzer K, Ferenci P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. J Hepatol, 2015;62, S619–S620 (EASL abstract P0772).
33. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1–11.
34. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–1161.
35. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405–412.
36. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.
37. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
38. Brown A, Hezode C, Zuckermann E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5, or 6 infection. J Hepatol, 2015;62,S619-S620 (EASL abstract P0771).
39. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590–1598.
40. Khatri A, Dutta S, Marbury TC, et al. Pharmacokinetics and tolerability of anti-hepatitis C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, in subjects with renal impairment. Clin Pharmacokinet. 2016;doi: 10.1007/s40262-016-0429-9. epub ahead of print.
41. Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Effects of mild and moderate renal impairment on ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin pharmacokinetics in patients with chronic HCV infection. Eur J Drug Metab Pharmacokinet. 2016;doi: 10.1007/s13318-016-0341-6 epub ahead of print.
42. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int. 2016;36:798–801.
43. Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763–765.
44. Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis. 2015;47:924–929.
45. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816.
46. Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40–47.
47. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36:802–806.
48. Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159:729–738.
49. Liu CH, Liu CJ, Huang CF, et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut. 2015;64:303–311.
50. Fabrizi F, Dixit V, Messa P, Martin P. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J Viral Hepat. 2014;21:681–689.
51. Goel A, Bhadauria DS, Kaul A, et al. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis. Nephrology. 2016;doi: 10.1111/nep.12833. epub ahead of print.
52. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768–774.
53. Yasumura T, Nakajima H, Hamashima T, et al. Long-term outcome of recombinant INF-alpha treatment of chronic hepatitis C in kidney transplant recipients. Transplant Proc. 1997;29:784–786.
54. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc. 1998;30:3270–3272.
55. Sanai FM, Mousa D, Al-Mdani A, et al. Safety and efficacy of peginterferon-alpha2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol. 2013;58:1096–1103.
56. Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int. 2009;22:562–567.
57. Regner KR, Singbartl K. Kidney injury in liver disease. Crit Care Clin. 2016;32:343–355.
58. Kwo P, Poordad F, Porcalla AR, et al. Safety of ABT-493 + ABT-530 co-administered in patients with HCV genotype 1-6 infection: results from the SURVEYOR-I and SURVEYOR-II studies. Gastroenterology. 2016;150,S1093.
59. Gane E, Poordad F, Asatryan A, et al. High efficacy and favourable safety of ABT-493 + ABT-530 co-administration for 12 weeks in HCV genotype 1-infected patients with cirrhosis (SURVEYOR-I). Available at: http://www.natap.org/2016/EASL/EASL_36.htm
60. Gane E, Laezari J, Asatryan A, et al. 100% SVR4 and favorable safety of ABT-493 + ABT-530 administered for 12 weeks in non-cirrhotic patients with genotypes 4, 5, or 6 infection (SURVEYOR-I). Gastroenterology. 2016;150,S1047.
61. Kalafateli M, Dusheiko G, Manousou P. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant. J Gastrointestin Liver Dis. 2015;24:257–258.
62. Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
63. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64:790–799.
64. Fernandez-Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the Hepa-C registry. J Hepatol. 2016;64, S133 (EASL abstract GS01).
65. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64:763–765.